Listing a study does not mean it has been evaluated by the U. Hydroxychloroquine may inactivate these pathways and results in the death of pancreatic cancer cells. Hydroxychloroquine is approved for the treatment of non-cancerous illnesses such as rheumatoid arthritis and systemic lupus erythematous. Plaquenil lichen planus Plaquenil for arthritis Does a daily dose if plaquenil help with joint pain Abstract. Pancreatic ductal adenocarcinoma PDAC is a leading cause of cancer death and lacks effective treatment. Although much of the mechanisms underlying PDAC development is still unknown, autophagy – the process of catabolizing damaged cellular components and bioenergetic macromolecules – has been found to impact PDAC growth. Hydroxychloroquine HCQ is the only clinically-approved autophagy inhibitor, and this systematic review focuses on HCQ use in cancer clinical trials. Preclinical trials have shown that HCQ alone and in combination therapy leads to enhancement of tumor shrinkage. We evaluated hydoxychloroquine HCQ, an inhibitor of autophagy, in patients with pancreatic cancer and analyzed pharmacodynamic markers in treated patients and mice. METHODS Patients with previously treated metastatic pancreatic cancer were administered HCQ at 400 mg n = 10 or 600 mg n = 10 twice daily. Patients received 600 mg hydroxychloroquine orally twice per day. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision. Patients received 400 mg hydroxychloroquine orally twice per day. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision. Hydroxychloroquine autophagy pancres A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine., Targeting Autophagy in Cancer Update on Clinical Trials. Plaquenil msdsChloroquine phosohate Researchers from Huntsman Cancer Institute HCI at the University of Utah have now come up with a potential new therapy for pancreatic cancer patients. One-year survival is low among patients. New therapeutic approach for patients with pancreatic cancer. Phase II and pharmacodynamic study of autophagy inhibition.. P53 status determines the role of autophagy in pancreatic.. Pancreatic cancer and autophagy The pancreas is a large, flat organ that sits deep inside the abdomen behind the stomach. It produces enzymes and hormones that help to digest food and control. Autophagy is a catabolic pathway that permits cells to recycle intracellular macromolecules, and its inhibition reduces pancreatic cancer growth in model systems. We evaluated hydoxychloroquine HCQ, an inhibitor of autophagy, in patients with pancreatic cancer and analyzed pharmacodynamic markers in treated patients and mice. We report safety and efficacy of adding an autophagy inhibitor, hydroxychloroquine HCQ to front-line platinum-based chemotherapy in a phase Ib single arm study in patients with metastatic NSCLC. Methods Patients with newly diagnosed metastatic NSCLC were treated with carboplatin, paclitaxel and bevacizumab if meeting criteria and HCQ 200.